AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21589675 — intervention group
Group type: COMPARATOR
Intervention: Fixed-head prosthesis (cemented or cementless)
Number of subjects: 50
Study 18321743 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0873 (2.5mg for 6 days) + Theophylline (250mg on day 5)
Number of subjects: 8
Study 18321743 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (250mg on day 1)
Number of subjects: 8
Study 16426959 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-enriched beverage for 14 months
Number of subjects: 0
Study 16426959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14713138 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management intervention with vouchers redeemable for tokens (values from 0.00 to 100.00 dollars)
Number of subjects: 102
Study 14713138 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable rate of reinforcement (as in Study 1)
Number of subjects: 102
Study 14713138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed value reinforcer of 3.25 dollars
Number of subjects: 102
Study 14713138 — intervention group
Group type: COMPARATOR
Intervention: Variable and fixed reinforcement groups
Number of subjects: 102
Study 11016399 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (59 mg Al/ml), 10 ml three times daily for 6 weeks
Number of subjects: 18
Study 11016399 — intervention group
Group type: COMPARATOR
Intervention: Referent group (no aluminum exposure)
Number of subjects: 18
Study 9184389 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity oral anticoagulant treatment (target INR = 3)
Number of subjects: 205
Study 9184389 — intervention group
Group type: COMPARATOR
Intervention: Moderate-high intensity oral anticoagulant treatment (target INR = 4)
Number of subjects: 205
Study 9184389 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (target INR = 3 and target INR = 4)
Number of subjects: 205
Study 1347670 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0
Study 1347670 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 0
Study 1347670 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluoperazine
Number of subjects: 0
Study 1347670 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 1347670 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7033947 — intervention group
Group type: EXPERIMENTAL
Intervention: bendrofluazide 5 mg
Number of subjects: 17
Study 7033947 — intervention group
Group type: EXPERIMENTAL
Intervention: indapamide 2.5 mg
Number of subjects: 17
Study 30293931 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zonisamide (4-25 mg/kg/day)
Number of subjects: 30
Study 30293931 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular adrenocorticotropic hormone (30-60 IU)
Number of subjects: 30
Study 28130990 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone treatment with different drug counseling models
Number of subjects: 328
Study 28130990 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis of psychiatric symptoms
Number of subjects: 328
Study 25892382 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute bout of submaximal cycling exercise
Number of subjects: 29
Study 25892382 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise, reaction time tests after 30 min)
Number of subjects: 29
Study 23669386 — intervention group
Group type: EXPERIMENTAL
Intervention: 20, 100, or 200 mg of oral oseltamivir BID for 5 days
Number of subjects: 140
Study 23669386 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg oseltamivir once daily for 5 days
Number of subjects: 140
Study 23669386 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 or 150 mg of oral oseltamivir BID for 5 days
Number of subjects: 140
Study 23669386 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 140
Study 22133339 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight training course using the e-learning tool DART
Number of subjects: 0
Study 22133339 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 18985374 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (PRED, 60 mg/day for 1 week)
Number of subjects: 8
Study 18985374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17891560 — intervention group
Group type: EXPERIMENTAL
Intervention: ULEM therapy and conventional physical therapy (PT)
Number of subjects: 44
Study 17891560 — intervention group
Group type: COMPARATOR
Intervention: PT only
Number of subjects: 44
Study 16898618 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron (5-HT3 receptor antagonist)
Number of subjects: 0
Study 16898618 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilansetron (5-HT3 antagonist)
Number of subjects: 0
Study 12800788 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone
Number of subjects: 0
Study 12800788 — intervention group
Group type: EXPERIMENTAL
Intervention: Protriptyline
Number of subjects: 0
Study 12800788 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 0
Study 12800788 — intervention group
Group type: COMPARATOR
Intervention: Drug treatments
Number of subjects: 0
Study 10052839 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g, single dose)
Number of subjects: 60
Study 10052839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7595029 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC‐201 (up to 45 gm or 350 ml)
Number of subjects: 24
Study 7595029 — intervention group
Group type: COMPARATOR
Intervention: Control solution (Ringer's lactate)
Number of subjects: 24
Study 2099071 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (3 tablets, 300,000 binding units of the toxoid and 10,000 units of O‐antigens)
Number of subjects: 276
Study 2099071 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine
Number of subjects: 276
Study 2099071 — intervention group
Group type: COMPARATOR
Intervention: Parenteral vaccines
Number of subjects: 276
Study 7010203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 59
Study 7010203 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study 31594037 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib (3, 6, 12, 24 mg b.i.d. or 24 mg q.d.)
Number of subjects: 216
Study 31594037 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 216
Study 28936712 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed nutrition (EGDN)
Number of subjects: 199
Study 28936712 — intervention group
Group type: COMPARATOR
Intervention: Standard nutritional care
Number of subjects: 199
Study 25947301 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention (A) - educational outreach visit with GPs and guideline by mail
Number of subjects: 3443
Study 25947301 — intervention group
Group type: COMPARATOR
Intervention: Simple intervention (B) - guideline by mail only
Number of subjects: 3443
Study 25947301 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 3443
Study 25947301 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention (A)
Number of subjects: 3443
Study 25947301 — intervention group
Group type: COMPARATOR
Intervention: Simple intervention (B)
Number of subjects: 3443
Study 24135599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated Enterococcus faecium at 1 × 10(9) cfu/kg of feed
Number of subjects: 288
Study 24135599 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistine sulfate at 10 mg/kg of feed
Number of subjects: 288
Study 24135599 — intervention group
Group type: COMPARATOR
Intervention: Positive control (challenged with E. coli K88)
Number of subjects: 288
Study 21711517 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-DHA (300 mg PS/day) for 15 weeks
Number of subjects: 157
Study 21711517 — intervention group
Group type: EXPERIMENTAL
Intervention: PS-DHA (100 mg PS/day) for 30 weeks (open-label extension)
Number of subjects: 157
Study 21711517 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 weeks
Number of subjects: 157
Study 18435185 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% hydrogen peroxide (HP) (Opalescence Xtra Boost)
Number of subjects: 18
Study 18435185 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% carbamide peroxide (CP) (Rembrandt Quik Start)
Number of subjects: 18
Study 18435185 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL) - baseline measurements
Number of subjects: 18
Study 16608782 — intervention group
Group type: EXPERIMENTAL
Intervention: Local collagen-gentamicin
Number of subjects: 0
Study 16608782 — intervention group
Group type: COMPARATOR
Intervention: Intravenous prophylaxis alone
Number of subjects: 0
Study 12876389 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of heterozygosity involving 1p
Number of subjects: 121
Study 12876389 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of heterozygosity involving 19q
Number of subjects: 121
Study 12876389 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1p and 19q loss
Number of subjects: 121
Study 12876389 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapeutic regimens
Number of subjects: 121
Study 12876389 — intervention group
Group type: COMPARATOR
Intervention: Subgroups stratified by age, tumor location, or tumor histology
Number of subjects: 121
Study 10966240 — intervention group
Group type: EXPERIMENTAL
Intervention: E5531 (100, 250, 500, or 1000 microg)
Number of subjects: 32
Study 10966240 — intervention group
Group type: EXPERIMENTAL
Intervention: E5531 (250, 500, or 1000 microg)
Number of subjects: 32
Study 10966240 — intervention group
Group type: EXPERIMENTAL
Intervention: E5531 (any dose)
Number of subjects: 32
Study 10966240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8999618 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms twice daily
Number of subjects: 304
Study 8999618 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 400 micrograms four times daily
Number of subjects: 304
Study 8999618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 1296467 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluprick SQ (ALK)
Number of subjects: 200
Study 1296467 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphatest (DHS)
Number of subjects: 200
Study 1296467 — intervention group
Group type: EXPERIMENTAL
Intervention: Phazet (PHA)
Number of subjects: 200
Study 6219578 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phosphate
Number of subjects: 15
Study 6219578 — intervention group
Group type: EXPERIMENTAL
Intervention: Mithramycin
Number of subjects: 15
Study 6219578 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 15
Study 6219578 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 15
Study 6219578 — intervention group
Group type: EXPERIMENTAL
Intervention: EHDP (ethane‐1‐hydroxy‐1, 1‐diphosphonate)
Number of subjects: 15
Study 6219578 — intervention group
Group type: EXPERIMENTAL
Intervention: APD (3‐amino‐1‐hydroxypropane‐1, 1‐diphosphonate)
Number of subjects: 15
Study 30538099 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 1157
Study 28858925 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) at subpurpuric settings
Number of subjects: 20
Study 28858925 — intervention group
Group type: COMPARATOR
Intervention: Control side (no treatment)
Number of subjects: 20
Study 26827294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal delivery of oxytocin (OT)
Number of subjects: 51
Study 26827294 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up experiment with perceived human-like characteristics of inanimate objects
Number of subjects: 51
Study 24662784 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia Nervosa (AN) patients
Number of subjects: 72
Study 24662784 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 72
Study 24662784 — intervention group
Group type: EXPERIMENTAL
Intervention: AN patients
Number of subjects: 72
Study 23139608 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic sachet Flortec(©) (Lactobacillus paracasei B21060) once daily plus high-fibre diet for 6 mo
Number of subjects: 45
Study 23139608 — intervention group
Group type: COMPARATOR
Intervention: High-fibre diet alone for 6 mo
Number of subjects: 45
Study 20879853 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal treatment
Number of subjects: 119
Study 17611607 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 578
Study 15077082 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10-20 mg per day)
Number of subjects: 253
Study 15077082 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 253
Study 11730494 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine wipe
Number of subjects: 1230
Study 11730494 — intervention group
Group type: COMPARATOR
Intervention: No wipe
Number of subjects: 1230
Study 9389973 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) treatment for 12 months
Number of subjects: 24
Study 7956625 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic group (type I diabetes)
Number of subjects: 13
Study 2883987 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol (50 mg)
Number of subjects: 8
Study 2883987 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol (5 mg)
Number of subjects: 8
Study 2883987 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol (200 mg)
Number of subjects: 8
Study 2883987 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 31941544 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity‐guided treat‐to‐target strategy with tapering attempt
Number of subjects: 95
Study 31941544 — intervention group
Group type: COMPARATOR
Intervention: Disease activity‐guided treat‐to‐target strategy without tapering attempt
Number of subjects: 95
Study 28609578 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of a fellow service member (FSM)
Number of subjects: 204
Study 28609578 — intervention group
Group type: COMPARATOR
Intervention: Other bereaved individuals (not FSM)
Number of subjects: 204
Study 28609578 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 204
Study 28609578 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereaved individuals
Number of subjects: 204
Study 26706911 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (6 to 8 sessions)
Number of subjects: 104
Study 26706911 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct outreach to aging services providers
Number of subjects: 104
Study 25708026 — intervention group
Group type: EXPERIMENTAL
Intervention: Piriformis fossa entry nailing
Number of subjects: 12
Study 25708026 — intervention group
Group type: COMPARATOR
Intervention: Trochanteric entry nailing
Number of subjects: 12
Study 23175674 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment
Number of subjects: 382
Study 23175674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 19711099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/day in 6-week cycles (Schedule 4/2)
Number of subjects: 292
Study 19711099 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 800 mg/day
Number of subjects: 292
Study 19711099 — intervention group
Group type: COMPARATOR
Intervention: IFN-alfa 9 MU t.i.w.
Number of subjects: 292
Study 19711099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 18791486 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene plus ossein-hydroxyapatite compound (RLX + OHC)
Number of subjects: 90
Study 18791486 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene plus calcium carbonate (RLX + CC)
Number of subjects: 90
Study 16773412 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary NGAL levels <200 ng/ml
Number of subjects: 34
Study 16773412 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary NGAL levels >=200 ng/ml
Number of subjects: 34
Study 16773412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis requirement
Number of subjects: 34
Study 14672296 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat supplement
Number of subjects: 544
Study 14672296 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplement
Number of subjects: 544
Study 14672296 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy supplement
Number of subjects: 544
Study 14672296 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 544
Study 10597759 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported blood pressure (SBP, DBP) and heart rate (HR) measurements recorded by subjects using a digital BP monitor for 1 week.
Number of subjects: 30
Study 10597759 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported SBP in uncontrolled hypertension group.
Number of subjects: 30
Study 10597759 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported DBP in uncontrolled hypertension group.
Number of subjects: 30
Study 10597759 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported HR in cases where stored HR exceeded 100 beats/min.
Number of subjects: 30
Study 8583618 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg allopurinol daily
Number of subjects: 54
Study 8583618 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg allopurinol daily
Number of subjects: 54
Study 8583618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 1957753 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg, alternate day)
Number of subjects: 22071
Study 1957753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study 7083769 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (oral and intravenous)
Number of subjects: 13
Study 7083769 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol absorption in untreated coeliac patients
Number of subjects: 13
Study 7083769 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol absorption overall
Number of subjects: 13
Study 30094545 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid (ZA) alone
Number of subjects: 261
Study 30094545 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) plus radiopharmaceuticals (Sr-89 or Sm-153)
Number of subjects: 261
Study 26332193 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin alone
Number of subjects: 13819
Study 26332193 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone, Bivalirudin alone, Heparin plus GPI, Bivalirudin plus GPI
Number of subjects: 13819
Study 26332193 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment phase
Number of subjects: 13819
Study 25179366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT) including thrombolysis with alteplase or urokinase, mechanical treatment, or both.
Number of subjects: 500
Study 25179366 — intervention group
Group type: COMPARATOR
Intervention: No intra-arterial treatment (no IAT).
Number of subjects: 500
Study 22103774 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 80
Study 22103774 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 80
Study 20473736 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang Capsule
Number of subjects: 84
Study 20473736 — intervention group
Group type: COMPARATOR
Intervention: Polyene phosphatidylcholine capsule
Number of subjects: 84
Study 18322252 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus melphalan and prednisone (VMP)
Number of subjects: 60
Study 18322252 — intervention group
Group type: COMPARATOR
Intervention: Melphalan plus prednisone (historical control)
Number of subjects: 60
Study 16011059 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative loco-regional radiation therapy
Number of subjects: 258
Study 16011059 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radiation therapy)
Number of subjects: 258
Study 12459659 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 12459659 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 20
Study 10398981 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mmol/kg Gd-BOPTA
Number of subjects: 50
Study 10398981 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg Gd-BOPTA
Number of subjects: 50
Study 10398981 — intervention group
Group type: EXPERIMENTAL
Intervention: GRE images
Number of subjects: 50
Study 7593899 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine plus midazolam (M)
Number of subjects: 21
Study 7593899 — intervention group
Group type: COMPARATOR
Intervention: propofol (P)
Number of subjects: 21
Study 2405741 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion at a dose of 30 ng.kg‐1.min‐1 for 7 days
Number of subjects: 0
Study 2405741 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 6994764 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (0.01 mg/kg)
Number of subjects: 5
Study 6994764 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (0.02 mg/kg)
Number of subjects: 5
Study 6994764 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (0.04 mg/kg)
Number of subjects: 5
Study 6994764 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (0.01, 0.02, 0.04 mg/kg)
Number of subjects: 5
Study 6994764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 6882619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 200 mg
Number of subjects: 24
Study 6882619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 400 mg
Number of subjects: 24
Study 6882619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29210932 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Outcome Measure for Elder Rehabilitation (BOOMER)
Number of subjects: 141
Study 29210932 — intervention group
Group type: EXPERIMENTAL
Intervention: Static standing with eyes closed test (component of BOOMER)
Number of subjects: 141